Canton Hathaway’s Vertex Pharmaceuticals VRTX Stock Holding History

Canton Hathaway’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$27.7K	Hold	62	–	–	0.01%	238
2025 Q4	$28.1K	Hold	62	–	–	0.01%	245
2025 Q3	$24K	Hold	62	–	–	﹤0.01%	258
2025 Q2	$28K	Hold	62	–	–	0.01%	244
2025 Q1	$30K	Hold	62	–	–	0.01%	238
2024 Q4	$25K	Hold	62	–	–	0.01%	222
2024 Q3	$29K	Hold	62	–	–	0.01%	213
2024 Q2	$29K	Hold	62	–	–	0.01%	207
2024 Q1	$26K	Hold	62	–	–	0.01%	218
2023 Q4	$25K	Hold	62	–	–	0.01%	212
2023 Q3	$22K	Hold	62	–	–	0.01%	216
2023 Q2	$22K	Buy	+62	New	+$20.9K	0.01%	221

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Canton Hathaway's VRTX Position: Q1 2026 in Review

Canton Hathaway held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 62 shares worth $27.7K. The position accounts for 0.01% of the portfolio, ranked #238.

Canton Hathaway first reported a position in VRTX in Q2 2023 and has held it in 12 quarters since. The position peaked at $30K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Canton Hathaway held 62 shares of Vertex Pharmaceuticals worth $27.7K as of Q1 2026.
Canton Hathaway left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up 0.01% of Canton Hathaway's portfolio in Q1 2026, its #238 holding.
Canton Hathaway first reported a position in Vertex Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
Canton Hathaway's Vertex Pharmaceuticals position peaked at $30K in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Canton Hathaway's 13F filing for Q1 2026, filed 24 Apr 2026.